Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI)
|ClinicalTrials.gov Identifier: NCT00251823|
Recruitment Status : Completed
First Posted : November 10, 2005
Last Update Posted : September 4, 2008
ST-elevation myocardial infarction (STEMI) is usually triggered by rupture of an atherosclerotic plaque that then accumulates platelets and fibrin and leads to an occlusive coronary thrombus. Clinical benefits obtained with revascularization of the infarct related artery (IRA) depend on the achievement of four goals:
- Early reperfusion
- Full restoration of normal flow in the epicardial vessels
- Full restoration of flow in the microcirculation, and
- Preservation of myocardial function.
Reperfusion of the IRA can be achieved pharmacologically with intravenous thrombolytic agents, or mechanically with percutaneous coronary intervention (PCI). In Canada, thrombolysis is the current standard of care in most hospitals, although there is mounting evidence that primary PCI is superior, and many Canadian centres are shifting towards this strategy. To offer primary PCI to community hospitals without on site cardiac catheterization facilities, regional programs need to be present that allow rapid transfer to invasive centers that offer this procedure round-the-clock.
Recent evidence suggests that angiographic and clinical results with primary PCI could be further enhanced by facilitation with a pharmacological treatment given prior to the procedure. The present proposal plans to examine the safety and efficacy of eptifibatide to facilitate coronary angioplasty in STEMI in patients who present to centres with and without on-site catheterization facilities.
The primary outcome measure will be a composite clinical endpoint including death, recurrent myocardial infarction, recurrent unstable ischemia, or stroke, at 30 days.
Secondary endpoints include the percent thrombolysis in myocardial infarction (TIMI) grade 3 coronary flow after the PCI, myocardial perfusion score, individual clinical outcomes as listed for the primary endpoint, resolution of ST-segment elevation, requirement for subsequent revascularization, frequency of congestive heart failure (CHF), cardiogenic shock, and Canadian Cardiovascular Society (CCS) angina class.
|Condition or disease||Intervention/treatment||Phase|
|Myocardial Infarction||Drug: Eptifibatide facilitated PCI||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||400 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Safety and Efficacy of Eptifibatide-Facilitated Percutaneous Coronary Angioplasty Versus Primary Percutaneous Coronary Angioplasty Alone|
|Study Start Date :||July 2005|
|Study Completion Date :||September 2008|
- The primary clinical endpoint is a composite measure of clinical outcomes of death, recurrent myocardial infarction, and recurrent severe ischemia, which will be assessed at 30 days after the index acute myocardial infarction (AMI)
- Determine if a facilitated PCI strategy with early initiation of eptifibatide improves the percentage of patients with TIMI grade 3 flow measured at the time of baseline angiography
- improves post procedural TIMI perfusion scoreC
- improves ST-segment elevation resolution, a surrogate marker of clinical efficacy
- improves left ventricular (LV) ejection fraction
- improves functional capacity
- decreases subsequent revascularization (PCI , or coronary artery bypass graft [CABG])
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00251823
|University of Ottawa Heart Institute|
|Ottawa, Ontario, Canada, K1Y 4W7|
|Principal Investigator:||Michel R. Le May, MD||Ottawa Heart Institute Research Corporation|